Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 54.83 as of 2026-10-06T15:33:34.372Z.
Consensus retrieved: 2026-10-06T13:14:07.187Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:33:34.372Z.
Quote observation: 2026-10-06T15:31:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 770a25882bbf240e7dd0e921658fc1146ed3cbaaf52ff006066619216260c690
Forward PE Ratio (54.83) = Dated Quote Price ($76.36) / Consensus Forward EPS ($1.39)
FORWARD PE RATIO
54.83
SECTOR MEDIAN · HEALTHCARE
19.81
median of 169 covered companies
CURRENT VS SECTOR MEDIAN
+176.78%
vs the sector median at left
Kiniksa Pharmaceuticals International, plc
Market Cap
$5.82B
Forward PE Ratio
54.83
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | $5.82B | 54.83 |
| CG Oncology Inc. (CGON)vs › | $5.86B | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.00B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.00B | 32.19 |
| GRAIL Inc. (GRAL)vs › | $6.02B | N/A |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | 29.32 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.44B | 51.26 |
| Doximity, Inc. (DOCS)vs › | $5.38B | 21.33 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.28B | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.28B | N/A |
Trailing P/E
77.9
reported TTM EPS
Forward P/E
54.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.39 implies +41.8% EPS growth vs the reported trailing $0.98.
At the dated quote price of $76.36, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.39 | $1.12 – $1.83 | 4 | 54.8x |
| 2027-12-31 | $2.05 | $1.24 – $3.05 | 4 | 37.2x |
| 2028-12-31 | $2.77 | $1.62 – $3.44 | 6 | 27.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
